Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Galapagos NV
Galapagos NV
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Drug Delivery
Galapagos and NovAliX enter integrated drug discovery collaboration
The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology
Research & Development
Galapagos expands fibrosis portfolio
Fibrosis small molecule programme has been announced as the focus of a partnership between Galapagos and Evotec
Research & Development
Pharnext announces R&D agreement with Galapagos
The main goal of this agreement is to generate an additional pipeline of novel synergistic drug combinations in a broad set of indications
Research & Development
Galapagos ends inflammation partnership with Janssen
Long-running alliance started in 2007
Research & Development
AbbVie and Galapagos to co-develop cystic fibrosis therapies
Firms aim to start Phase 1 trials at end of 2014
Research & Development
Galapagos appoints CEO of Service Division
David Smith returns to the Belgian firm in new role
Research & Development
Galapagos receives €2.5m grant for IBD research
IWT-funded project aims to identify new compounds for future treatment of IBD
Subscribe now